Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer
NCT06050239Phase 1Unknown
- Sponsor
- Nanjing First Hospital
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium Lu-177 PSMA-0057 in Metastatic Prostate Cancer (mPC), sponsored by Nanjing First Hospital. Primary endpoint: Prostate Specific Antigen dynamic at 2 weeks. Status: unknown.
02
Drugs
lutetium Lu-177 PSMA-0057
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT06050239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06050239.